New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
06:32 EDTPFE, GSK, MYL, JNJ, BMY, TEVA, ACT, GNK, NVSSome justices seem skeptical about payments to generic drug firms, NY Times says
Several Supreme Court justices seemed skeptical about the practice of brand name pharmaceutical companies paying generic companies to keep their cheaper drugs off the market for a longer time, according to The New York Times. Some of the justices appeared to be interested in issuing a narrow ruling in the case they are hearing regarding the issue that would not create a precedent, the newspaper added. Reference Link
News For PFE;ACT;JNJ;NVS;TEVA;MYL;GNK;BMY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
June 19, 2015
11:39 EDTBMYBristol-Myers announces European Commission approval of Opdivo
Subscribe for More Information
08:30 EDTTEVA, MYLTeva completes purchase of 4.61% interest in Mylan
Subscribe for More Information
07:23 EDTTEVATeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
05:47 EDTMYLStocks with implied volatility movement; MYLCMG
Subscribe for More Information
June 18, 2015
17:05 EDTNVS, TEVANovartis announces U.S. launch of Glatopa
Sandoz, a Novartis (NVS) company, announced the U.S. launch of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy.
15:41 EDTMYL, TEVATeva tender offer for Mylan likely imminent, says Citi
Citi said Teva (TEVA) is likely to build up a 4.6% stake in Mylan (MYL) by today and that a formal tender offer is likely coming soon. An official bid could come with a provision requiring board changes and a tender will likely trigger a "poison pill" by Mylan, the firm added. Citi has a Buy rating and $70 price target on Teva shares.
13:08 EDTGSKGlaxoSmithKline management to meet with Piper Jaffray
Meeting to be held in Minneapolis on June 23 hosted by Piper Jaffray.
12:51 EDTTEVATeva guidance assumed launch of Copaxone generic, says BMO Capital
Subscribe for More Information
11:57 EDTMYL, TEVAMylan comments on ruling by appeals court on Copaxone patent
Subscribe for More Information
11:54 EDTTEVA, NVS, MYLAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
10:41 EDTTEVAMomenta reports CAFC decision to invalidated remanded Teva patent
Subscribe for More Information
10:01 EDTMYLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
09:11 EDTTEVAAlexza Pharmaceuticals amends Adasuve commercial partnership agreements
Subscribe for More Information
08:34 EDTTEVATeva to present new data from Phase 2b migraine prevention studies at AHS
Subscribe for More Information
08:02 EDTTEVATeva, Microchips Biotech announce partnership agreement
Subscribe for More Information
07:46 EDTMYLMylan initiated with a Buy at BTIG
Subscribe for More Information
07:36 EDTTEVAReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
06:57 EDTNVSMallinckrodt says Questcor facing multi-state antitrust probe
Subscribe for More Information
06:09 EDTMYL, TEVATeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use